What is animal experimentation telling us about new drug treatments of status epilepticus?

Epilepsia

Volumn 48, Issue SUPPL. 8, 2007, Pages 78-81

  Nehlig, Astrid ^a  

^a INSERM   (France)

Author keywords

Animal models; Neuronal loss; Neuroprotection; Status epilepticus

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ATIPAMEZOLE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; DIAZEPAM; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GLUTAMATE TRANSPORTER; KETAMINE; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PARALDEHYDE; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PROPOFOL; RETIGABINE; THIOPENTAL; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

BEHAVIOR; BRAIN DAMAGE; BRAIN NERVE CELL; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; MORBIDITY; MORTALITY; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SEIZURE SUSCEPTIBILITY; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; CELL DEATH; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; STATUS EPILEPTICUS;

EID: 35748975136     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01358.x     Document Type: Conference Paper

References (24)

1. André V, Ferrandon A, Marescaux C, Nehlig A. 2001) Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 47 : 99 117.
2. André V, Rigoulot MA, Koning E, Ferrandon A, Nehlig A 2003) Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia 44 : 893 903.
3. Borris DJ, Bertram EH, Kapur J 2000) Ketamine controls prolonged status epilepticus. Epilepsy Res 42 : 117 122.
4. Brandt C, Gastens AM, Sun M, Hausknecht M, Löscher W 2006) Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 51 : 789 804.
5. Chen JW, Wasterlain CG 2006) Status epilepticus: pathophysiology and management in adults. Lancet Neurol 5 : 246 256.
6. DeLorenzo RJ 2006) Incidence and causes of status epilepticus. In (Wasterlain CG, Treiman DM eds). Status Epilepticus: Mechanisms and Management. The MIT Press, Cambridge, MA, pp. 17 31.
7. François J, Ferrandon A, Koning E, Nehlig A 2005) A new drug RWJ 333369 protects limbic areas in the lithium-pilocarpine model (li-pilo) of epilepsy and delays or prevents the occurrence of spontaneous seizures. Epilepsia 46 (Suppl 8 269 270.
8. François J, Koning E, Ferrandon A, Nehlig A 2006a). The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 72 : 147 163.
9. François J, Ferrandon A, Koning E, Nehlig A (2006b). Epileptic outcome correlates to neuronal protection and can be predicted by EEG pattern: evidence from studies with RWJ 333369 in the lithium-pilocarpine model. FENS Abstracts 3 : A131 A133.
10. Halonen T, Nissinen J, Pitkänen A 2001) Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats. Neuropharmacology 40 : 536 550.
11. Kalviainen R, Eriksson K, Parviainen I 2005) Refractory generalised convulsive status epilepticus: a guide to treatment. CNS Drugs 19 : 759 768.
12. Klitgaard HV, Matagne AC, Vanneste-Goemaere J, Margineanu DG 2001) Effects of prolonged administration of levetiracetam on pilocarpine-induced epileptogenesis in rat. Epilepsia 42 (Suppl 7 114 115.
13. Löscher W, Schmidt D 2004) New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res 60 : 77 159.
14. Lowenstein DH. (2005) Treatment options for status epilepticus. Curr Opin Pharmacol 5 : 334 339.
15. Mazarati AM, Wasterlain CG 1999) N-methyl-D-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 265 : 187 190.
16. Mazarati AM, Sofia RD, Wasterlain CG 2002) Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus. Seizure 11 : 423 430.
17. Mazarati AM, Baldwin RA, Klitgaard H, Matagne A, Wasterlain CG 2003) Treatment with levetiracetam during the latent period after experimental status epilepticus reduces chronic spontaneous recurrent seizures. Epilepsia 44 (Suppl 9 223.
18. Meencke HJ, Veith G 2006) Clinical neuropathology in convulsive status epilepticus. In (Wasterlain CG, Treiman DM eds). Status Epilepticus: Mechanisms and Management. The MIT Press, Cambridge, MA, pp. 163 167.
19. Noe KH, Manno EM 2005) Mechanisms underlying status epilepticus. Drugs Today (Barcelona) 41 : 257 266.
20. Pitkänen A, Kubova H 2004) Antiepileptic drugs in neuroprotection. Expert Opin Pharmacotherapy 5 : 777 798.
21. Pitkänen A, Narkilahti S, Bezvenyuk Z, Haapalinna A, Nissinen J 2004) Atipamezole, an α2-adrenoceptor antagonist, has disease modifying effects on epileptogenesis in rats. Epilepsy Res 61 : 119 140.
22. Pitkänen A, Kharatishvili I, Narkilahti S, Lukasiuk K, Nissinen J 2005) Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res 63 : 27 42.
23. Prasad A, Williamson JM, Bertram EH 2002) Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus. Ann Neurol 51 : 175 181.
24. Rigoulot MA, Leroy C, Koning E, Ferrandon A, Nehlig A 2003) Prolonged low-dose caffeine exposure protects against hippocampal damage but not against the occurrence of epilepsy in the lithium-pilocarpine model in the rat. Epilepsia 44 : 529 535.